Human transcriptome array for high-throughput clinical studies
Name
Xu-2011-March-Human transcriptome.pdf
Size
522.98 KB
Format
Adobe PDF
Checksum (MD5)
8cc5c0db5ffed6d6b9126899a11badf2
Author(s)
Xu, Weihong
Seok, Junhee
Mindrinos, Michael N.
Schweitzer, Anthony C.
Jiang, Hui
Wilhelmy, Julie
Clark, Tyson A.
Kapur, Karen
Xing, Yi
Faham, Malek
Date Issued
March 2011
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
National Academy of Sciences (U.S.)
Citation
Xu, W. et al. “Human transcriptome array for high-throughput clinical studies.” Proceedings of the National Academy of Sciences 108 (2011): 3707-3712. ©2011 by the National Academy of Sciences.
Version
Final published version
Abstract
A 6.9 million-feature oligonucleotide array of the human transcriptome [Glue Grant human transcriptome (GG-H array)] has been developed for high-throughput and cost-effective analyses in clinical studies. This array allows comprehensive examination of gene expression and genome-wide identification of alternative splicing as well as detection of coding SNPs and noncoding transcripts. The performance of the array was examined and compared with mRNA sequencing (RNA-Seq) results over multiple independent replicates of liver and muscle samples. Compared with RNA-Seq of 46 million uniquely mappable reads per replicate, the GG-H array is highly reproducible in estimating gene and exon abundance. Although both platforms detect similar expression changes at the gene level, the GG-H array is more sensitive at the exon level. Deeper sequencing is required to adequately cover low-abundance transcripts. The array has been implemented in a multicenter clinical program and has generated high-quality, reproducible data. Considering the clinical trial requirements of cost, sample availability, and throughput, the GG-H array has a wide range of applications. An emerging approach for large-scale clinical genomic studies is to first use RNA-Seq to the sufficient depth for the discovery of transcriptome elements relevant to the disease process followed by high-throughput and reliable screening of these elements on thousands of patient samples using custom-designed arrays.
MIT Department
Massachusetts Institute of Technology. Clinical Research Center
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1019753108
